For Healthcare Professionals

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma


About the study

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Subject is ≥18 years of age
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

Must have a documented diagnosis of CLL/SLL requiring treatment (IwCLL Guidelines for the Diagnosis and Treatment of CLL). In addition presence of clinically measurable disease determined by at least one of the factors listed:

  1. nodal lesion that measures ≥ 1.5 cm in longest dimension (LD) and ≥ 1.0 cm in longest perpendicular dimension (LPD), or
  2. spleen that measures ≥ 14 cm in longest vertical dimension (LVD) with a minimum of 2 cm enlargement, or
  3. liver that measures ≥ 20 cm in LVD with a minimum of 2 cm enlargement, or
  4. peripheral blood B lymphocyte count > 5000/uL
  5. All eligible subjects must be relapsed after or be refractory to >2 prior lines of therapy one of which must have included an approved BTK inhibitor.

Must meet the following laboratory parameters:

  1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3 or ≥ 1000 cells/mm^3 if secondary to bone marrow involvement by disease, without growth factor support for 7 days (14 days if pegfilgastrim).
  2. Platelet count ≥ 75,000 cells/mm^3 (100 x 10^9/L) or ≥ 50,000 cells/mm^3 (50 x 10^9/L) if secondary to bone marrow involvement by disease, without transfusion for 7 days.
  3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) < 3.0 x upper limit of normal (ULN).
  4. Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome.
  5. Calculated creatinine clearance of ≥ 60 ml/min.


Exclusion Criteria:

  1. Presence of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Prior allogeneic stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICF. Subjects who received allogeneic SCT ≥ 12 months before signing the ICF may be eligible provided there is no ongoing graft-versus-host disease and no ongoing immune suppression therapy.
  3. Subject has received prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to starting CC-99282.
  4. Subject has received prior therapy with CRBN-modulating drug (eg, lenalidomide, avadomide/CC-122, pomalidomide) ≤ 4 weeks prior to starting CC-99282.
  5. History of second malignancies with life expectancy of ≤ 2 years or requirement of therapy that would confound study results.
  6. Peripheral neuropathy ≥ Grade 2.
  7. History of hypersensitivity to lenalidomide, pomalidomide, thalidomide.
  8. Impaired cardiac function or clinically significant cardiac disease.
  9. Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management.
  10. Active disease transformation (ie, Richter's Syndrome)
  11. Uncontrolled/active autoimmune hemolytic anemia or thrombocytopenia

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Lymphoma, Non-Hodgkin

Age (in years)



Phase 1

Participants needed


Est. Completion Date

May 13, 2025

Treatment type



Celgene identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.